Percentage of newly diagnosed CP-CML patients who reported the listed side effects of imatinib. The data are from 5 prospective, company-sponsored, Good Clinical Practice, contract research organization–monitored studies testing imatinib vs interferon-α plus low-dose arabinosyl cytosine (IRIS)¹⁵  vs nilotinib (ENESTnd)¹⁶  vs dasatinib (DASISION and SWOG)^14,17  and vs bosutinib (BELA).¹⁸  In the original reports, the figure represented the proportion or percentage of patients reporting each side effect. In all studies, the sum of the figures was >100%, because many patients reported >1 side effect. The differences among each side effect underscore the variability in collecting and reporting side effects, although all patients were treated frontline with the same dose of imatinib (400 mg/d). The differences among studies are quite impressive. The difference is also impressive for grade 3/4 side effects: from a total of 18.1% in IRIS to a total of 3.6% in ENESTnd (data not shown). Adapted from Baccarani et al.¹³  Image and legend obtained from the Haematologica Journal website (www.haematologica.org) and reproduced with permission of the rights holder (Ferrata Storti Foundation, Pavia, Italy).